JPS63503308A - 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 - Google Patents

抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法

Info

Publication number: JPS63503308A
Authority: JP; Japan
Prior art keywords: lps; tnf; tumor; group; natural
Prior art date: 1986-05-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP62503031A

Other languages

English (en)

Japanese (ja)

Inventor

ホフマン，マイケル・ケー．

チユン，ミユン

ハマーリング，アルリツチ

Original Assignee

スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-09

Filing date

1987-05-07

Publication date

1988-12-02

1987-05-07 Application filed by スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ filed Critical スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ

1988-12-02 Publication of JPS63503308A publication Critical patent/JPS63503308A/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 23
239000000203 mixture Substances 0.000 title claims description 22
238000011282 treatment Methods 0.000 title claims description 21
230000000259 anti-tumor effect Effects 0.000 title claims description 20
238000002560 therapeutic procedure Methods 0.000 title claims description 8
239000002158 endotoxin Substances 0.000 title claims 20
229920006008 lipopolysaccharide Polymers 0.000 title claims 20
206010028980 Neoplasm Diseases 0.000 claims description 97
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 62
229960000905 indomethacin Drugs 0.000 claims description 31
230000000694 effects Effects 0.000 claims description 20
108010002352 Interleukin-1 Proteins 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 18
238000006243 chemical reaction Methods 0.000 claims description 17
231100000252 nontoxic Toxicity 0.000 claims description 17
230000003000 nontoxic effect Effects 0.000 claims description 17
108010002350 Interleukin-2 Proteins 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 12
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 11
229960004397 cyclophosphamide Drugs 0.000 claims description 11
230000004044 response Effects 0.000 claims description 11
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 8
231100000419 toxicity Toxicity 0.000 claims description 8
230000001988 toxicity Effects 0.000 claims description 8
210000000987 immune system Anatomy 0.000 claims description 6
230000002195 synergetic effect Effects 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000005445 natural material Substances 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 4
239000002089 prostaglandin antagonist Substances 0.000 claims description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
229940041181 antineoplastic drug Drugs 0.000 claims description 2
229940127089 cytotoxic agent Drugs 0.000 claims 6
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 5
102000004211 Platelet factor 4 Human genes 0.000 claims 4
108090000778 Platelet factor 4 Proteins 0.000 claims 4
KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical group [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 claims 1
239000003102 growth factor Substances 0.000 claims 1
230000005965 immune activity Effects 0.000 claims 1
229930014626 natural product Natural products 0.000 claims 1
230000000144 pharmacologic effect Effects 0.000 claims 1
230000000638 stimulation Effects 0.000 claims 1
239000003440 toxic substance Substances 0.000 claims 1
229940063674 voltaren Drugs 0.000 claims 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 86
102000003390 tumor necrosis factor Human genes 0.000 description 86
206010028851 Necrosis Diseases 0.000 description 31
230000017074 necrotic cell death Effects 0.000 description 31
241000699670 Mus sp. Species 0.000 description 30
206010054094 Tumour necrosis Diseases 0.000 description 24
241000699666 Mus <mouse, genus> Species 0.000 description 19
210000004027 cell Anatomy 0.000 description 16
210000002966 serum Anatomy 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
201000011510 cancer Diseases 0.000 description 15
102000000589 Interleukin-1 Human genes 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
230000001404 mediated effect Effects 0.000 description 10
210000000822 natural killer cell Anatomy 0.000 description 10
231100000331 toxic Toxicity 0.000 description 10
230000002588 toxic effect Effects 0.000 description 10
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
230000006870 function Effects 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
230000001338 necrotic effect Effects 0.000 description 7
230000007123 defense Effects 0.000 description 6
239000000411 inducer Substances 0.000 description 6
230000004913 activation Effects 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
230000006051 NK cell activation Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000008260 defense mechanism Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
238000011287 therapeutic dose Methods 0.000 description 4
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000006023 anti-tumor response Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000008713 feedback mechanism Effects 0.000 description 2
231100000086 high toxicity Toxicity 0.000 description 2
230000005934 immune activation Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 1
241001070941 Castanea Species 0.000 description 1
235000014036 Castanea Nutrition 0.000 description 1
UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001715 anti-suppressor Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
235000021110 pickles Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
208000018655 severe necrosis Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
UDEJEOLNSNYQSX-UHFFFAOYSA-J tetrasodium;2,4,6,8-tetraoxido-1,3,5,7,2$l^{5},4$l^{5},6$l^{5},8$l^{5}-tetraoxatetraphosphocane 2,4,6,8-tetraoxide Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)O1 UDEJEOLNSNYQSX-UHFFFAOYSA-J 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP62503031A 1986-05-09 1987-05-07 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 Pending JPS63503308A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86156686A	1986-05-09	1986-05-09
US861,566		1986-05-09

Publications (1)

Publication Number	Publication Date
JPS63503308A true JPS63503308A (ja)	1988-12-02

Family

ID=25336155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62503031A Pending JPS63503308A (ja)	1986-05-09	1987-05-07	抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法

Country Status (4)

Country	Link
EP (1)	EP0271521A4 (fr)
JP (1)	JPS63503308A (fr)
AU (1)	AU7397887A (fr)
WO (1)	WO1987006830A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006502080A (ja) *	2001-11-27	2006-01-19	シェーリング　コーポレイション	腫瘍由来樹状細胞阻害因子アンタゴニストおよびＴｏｌｌ様レセプターアゴニストの併用を使用する、癌を処置するための方法
JP2006518350A (ja) *	2003-02-18	2006-08-10	クリニークラプレリーリサーチエスエー	胎児ヘモグロビン、細菌エンドトキシン、および任意でさらなる胎児肝成分を含む組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4844895A (en) *	1985-11-01	1989-07-04	New York University	Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
ATE91237T1 (de) *	1986-10-16	1993-07-15	Harvard College	Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
AU2002232560A1 (en)	2000-10-27	2002-05-06	Immuno-Rx, Inc	Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en)	2000-10-27	2007-02-01	Hadden John W	Vaccine immunotherapy
CA2472578A1 (fr) *	2002-01-24	2003-07-31	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combinaison anticancereuse et son utilisation
US20050059613A1 (en) *	2003-07-08	2005-03-17	Bahram Memarzadeh	Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
EP1881080A1 (fr)	2006-07-18	2008-01-23	Institut Gustave Roussy	Troubles du récepteur de type toll (TLR)-4 et relatives applications biologiques
JP5563472B2 (ja)	2007-11-28	2014-07-30	アイアールエックスセーラピューティクス，インコーポレイテッド	免疫学的効果を増大させる方法
CA3017298C (fr)	2009-05-15	2021-09-28	Irx Therapeutics, Inc.	Compositions comprenant des produits biologiques derives de cellules primaires servant a ameliorer la reponse immunitaire des patients
ES2667476T3 (es)	2009-12-08	2018-05-11	Irx Therapeutics, Inc.	Método para invertir la supresión inmunitaria de células de Langerhans

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH643138A5 (de) *	1983-08-29	1984-05-30	Mepha Ag	Indomethacin enthaltende, gelartige salbe.

1987
- 1987-05-07 EP EP19870903576 patent/EP0271521A4/fr not_active Withdrawn
- 1987-05-07 WO PCT/US1987/001050 patent/WO1987006830A1/fr not_active Ceased
- 1987-05-07 JP JP62503031A patent/JPS63503308A/ja active Pending
- 1987-05-07 AU AU73978/87A patent/AU7397887A/en not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006502080A (ja) *	2001-11-27	2006-01-19	シェーリング　コーポレイション	腫瘍由来樹状細胞阻害因子アンタゴニストおよびＴｏｌｌ様レセプターアゴニストの併用を使用する、癌を処置するための方法
JP2006518350A (ja) *	2003-02-18	2006-08-10	クリニークラプレリーリサーチエスエー	胎児ヘモグロビン、細菌エンドトキシン、および任意でさらなる胎児肝成分を含む組成物

Also Published As

Publication number	Publication date
WO1987006830A1 (fr)	1987-11-19
EP0271521A4 (fr)	1989-11-14
AU7397887A (en)	1987-12-01
EP0271521A1 (fr)	1988-06-22

Publication	Publication Date	Title
US4980160A (en)	1990-12-25	Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
Costelli et al.	1993	Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.
Souto et al.	2011	Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors
Schade et al.	2020	Endotoxin tolerance
JPS63503308A (ja)	1988-12-02	抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法
Haba et al.	1976	Selective suppression of t‐cell activity in tumor‐bearing mice and its improvement by lentinan, a potent anti‐tumor polysaccharide
EA030513B1 (ru)	2018-08-31	Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний
Futami et al.	1990	Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
US5961969A (en)	1999-10-05	Stable circulating histamine levels
Hersh	1971	Immunosuppression by L-asparaginase and related enzymes: A review
Sredni et al.	1990	Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin
EP0287633B1 (fr)	1993-07-07	Combinaisons de facteurs de necroses de tumeurs et d'agents anti-inflammatoires pour le traitement de maladies malignes et non malignes
EP0303687B1 (fr)	1992-11-11	Compositions pour ameliorer les therapies adcc
US5061488A (en)	1991-10-29	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en)	1992-03-17	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
EP1347773B1 (fr)	2010-04-14	Compositions et methodes permettant d'ameliorer l'activite d'une cytokine et de traiter l'hypotension associee a l'administration de cytokines
Bloksma et al.	1987	Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A: U against solid Meth A tumors in mice
KIKUCHI et al.	1987	Effects of naloxone on human ovarian cancer cell growth in vitro and in vivo
Lane et al.	1960	The Antitumor Activity of 5-Bis-(2′-chloroethyl)-Aminouracil (Uracil Mustard)
JP2010529984A (ja)	2010-09-02	癌を治療するためのインターフェロンアルファ逐次レジメン
US3326761A (en)	1967-06-20	6-demethyl-6-deoxytetracycline, anti-tumor antibiotic
Schultz et al.	1983	Potentiation of nonspecific immunotherapy of experimental lung metastases by indomethacin
JPS61502123A (ja)	1986-09-25	抗腫瘍活性を有する薬剤学的生成物；抗腫瘍療法への薬剤学的生成物または薬剤学的組成物の使用
CN108992671A (zh)	2018-12-14	一种药物组合物及其制备治疗肝损伤的药物中的用途
De Fabritiis et al.	1989	In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine

JPS63503308A - 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=25336155

Family Applications (1)

Country Status (4)

Cited By (2)

Families Citing this family (10)

Family Cites Families (1)

Cited By (2)

Also Published As

Similar Documents